Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Nyxoah ( (NYXH) ).
On September 15, 2025, Nyxoah SA announced that it has filed a patent infringement lawsuit against Inspire Medical Systems, Inc. The lawsuit, filed in the United States District Court for the District of Delaware, claims that Inspire’s devices infringe on three of Nyxoah’s patents. This legal action underscores Nyxoah’s commitment to protecting its intellectual property and its innovative Genio system, which offers a unique treatment for OSA. The lawsuit could have significant implications for Nyxoah’s market positioning and its competitive landscape in the medical technology industry.
The most recent analyst rating on (NYXH) stock is a Buy with a EUR12.00 price target. To see the full list of analyst forecasts on Nyxoah stock, see the NYXH Stock Forecast page.
More about Nyxoah
Nyxoah is a medical technology company focused on developing and commercializing innovative solutions for treating Obstructive Sleep Apnea (OSA). Its lead product, the Genio system, is a patient-centered, leadless, and battery-free hypoglossal neurostimulation therapy designed to address OSA, a prevalent sleep disorder associated with increased mortality risk and cardiovascular issues. Nyxoah has achieved significant milestones, including receiving a European CE Mark in 2019 and FDA approval in August 2025.
YTD Price Performance: -42.55%
Average Trading Volume: 59,876
Current Market Cap: €177.6M
For an in-depth examination of NYXH stock, go to TipRanks’ Overview page.